Page 164 - Genentech News Today

Operator: Good morning and thank you for standing by. Welcome to the Nautilus First Quarter 2023 Earnings Conference Call.

Operator: Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call.

The FDA has accepted a supplemental biologics license application from Genentech for Vabysmo for the treatment of macular edema following retinal vein occlusion, according to a company press release.

A panel on women’s health disparities at the 2023 Asembia Specialty Pharmacy Summit addressed the current challenges women face regarding health care as well as how digital tools, collaboration between clinics and governments, and more detailed and inclusive research can help improve health equity for all women.

CHICAGO — More than 20% of patients with inflammatory bowel disease experienced recurrent Clostridioides difficile infection 1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week. “While there are data on the short-term efficacy of FMT for eradicating C. diff infections in patients with IBD, there is less known about longer-term

An AI tool identified people at the highest risk for pancreatic cancer up to three years before actual diagnosis. The findings point to the promise of AI for mass screening to help expedite the diagnosis of an aggressive disease often identified with serious delays. Pancreatic cancer is one of the deadliest cancers in the world and its toll is projected to increase.

DESTIN, Fla. — The long COVID epidemic continues to raise more questions than answers for rheumatologists, and while there are no definite solutions, data regarding prevention is painting a clear picture, according to a speaker here.“We think that the pandemic is over, and it really is not over,” Leonard Calabrese, DO, of the Cleveland Clinic and chief medical editor of Healio

COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinationsBioNTech and partner OncoC4 plan to start a

Columnist Ed Tobias comments on the week's top MS news, including a study looking at the benefits of starting early treatment of Ocrevus.

Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics...